Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study

被引:9
|
作者
Prosberg, Michelle V. [1 ]
Vester-Andersen, Marianne K. [1 ]
Andersson, Mikael [2 ]
Jess, Tine [2 ]
Andersen, Jon T. [3 ]
Vind, Ida [1 ]
Bendtsen, Flemming [1 ]
机构
[1] Univ Copenhagen, Hvidovre Hosp, Gastrounit, Med Sect, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark
[2] Natl Hlth Surveillance & Res, Dept Epidemiol Res, Copenhagen, Denmark
[3] Rigshosp, Dept Clin Pharmacol, DK-2100 Copenhagen, Denmark
关键词
ulcerative colitis; compliance; recurrence; INFLAMMATORY-BOWEL-DISEASE; MEDICATION NONADHERENCE; SURGERY RATES; MESALAZINE; MESALAMINE; ADHERENCE; DIAGNOSIS; PERSISTENCE; PREDICTORS; PHENOTYPE;
D O I
10.1097/MIB.0000000000000700
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Noncompliance to long-term medical therapy is a well-known problem among patients treated for ulcerative colitis, but studies of long-term consequences in unselected patients are lacking. The authors aimed to determine the risk of recurrence according to long-term compliance with oral 5-aminosalicylic acid among unselected patients with ulcerative colitis. Methods: The authors conducted a 7-year follow-up study of a population-based inception cohort of 243 Danish patients with ulcerative colitis diagnosed from 2003 to 2004. Compliance was defined as consumption of >= 80% of prescribed oral 5-aminosalicylic acid. Data were collected from medical records and the Danish National Prescription Database. They performed Cox regression analysis with adjustments for demographic and clinical characteristics to examine risk of recurrence (defined by increased use of oral 5-Aminosalicylic Acid, other additional treatment, or colectomy) in compliant versus noncompliant patients. Results: In total, 182 patients (75%) experienced at least 1 recurrence during follow-up. For the first year after diagnosis, risk of recurrence did not differ significantly between compliant and noncompliant patients. For 1 to 3 years (hazard ratio: 0.46, 95% CI, 0.33-0.63) and 3 to 8 years (hazard ratio: 0.42, 95% CI, 0.32-0.55) after diagnosis, risk of recurrence was significantly decreased among noncompliant patients compared with that of compliant patients. Conclusions: This unselected cohort study revealed a reverse association between compliance and recurrence of ulcerative colitis. This is unlikely to be explained by severe confounding because the authors were able to adjust for several demographic and clinical factors. Results may instead reflect that patients during recurrence-free periods through self-management choose not to take their medication.
引用
收藏
页码:925 / 932
页数:8
相关论文
共 50 条
  • [1] Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis
    Olmstead, Jill
    JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS, 2010, 22 (11): : 586 - 592
  • [2] Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database
    Kane, Sunanda V.
    Sumner, Michael
    Solomon, Dory
    Jenkins, Matthew
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (12) : 3463 - 3470
  • [3] Medication Use Patterns and Predictors of Nonpersistence and Nonadherence with Oral 5-Aminosalicylic Acid Therapy in Patients with Ulcerative Colitis
    Yen, Linnette
    Wu, Joanne
    Hodgkins, Paul
    Cohen, Russell D.
    Nichol, Michael B.
    JOURNAL OF MANAGED CARE PHARMACY, 2012, 18 (09): : 701 - 712
  • [4] Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study
    Fossmark, Reidar
    Olaisen, Maya
    Martinsen, Tom Christian
    Melberg, Hans Olav
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [5] Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment
    Elkjaer, Margarita
    Burisch, Johan
    Avnstrom, Soren
    Lynge, Elsebeth
    Munkholm, Pia
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (06) : 695 - 704
  • [6] No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study
    Jairath, Vipul
    Hokkanen, Suvi R. K.
    Guizzetti, Leonardo
    Boxall, Naomi
    Campbell-Hill, Sarah
    Patel, Haridarshan
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (04) : 416 - 424
  • [7] Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis
    Lee, Jin
    Jee, Sam Ryong
    Kim, Hyung Wook
    Baek, Dong Hoon
    Song, Geun Am
    Moon, Won
    Park, Seun Ja
    Kim, Hyun Jin
    Lee, Jong Hoon
    Park, Jong Ha
    Kim, Tae Oh
    PLOS ONE, 2019, 14 (03):
  • [8] Persistence of newly prescribed 5-aminosalicylic acid in patients with ulcerative colitis: A nationwide comprehensive database study
    Noda, Tatsuya
    Kuwaki, Kotaro
    Machida, Munehito
    Okumura, Yasuyuki
    Nishioka, Yuichi
    Myojin, Tomoya
    Imamura, Tomoaki
    PLOS ONE, 2024, 19 (12):
  • [9] PREVENTION OF RELAPSE IN ULCERATIVE-COLITIS USING ORAL OR TOPICAL 5-AMINOSALICYLIC ACID THERAPY
    SUTHERLAND, LR
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 1993, 7 (02): : 232 - 236
  • [10] Analysis of the Medication Persistence Rate for and Adherence to Oral 5-Aminosalicylic Acid Preparations in Japanese Patients with Ulcerative Colitis: Study Using a Nationwide Claims Database
    Ota, Takumi
    Takebe, Takahiro
    Shimizu, Yutaka
    Orido, Takashi
    Tanaka, Hiroyuki
    Nakamura, Shiro
    DIGESTION, 2024, 105 (03) : 232 - 242